Advertisement
U.S. markets close in 5 hours 6 minutes

Biocon Limited (BIOCON.NS)

NSE - NSE Real Time Price. Currency in INR
264.15+7.55 (+2.94%)
At close: 03:30PM IST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close256.60
Open260.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range259.20 - 266.75
52 Week Range201.60 - 307.10
Volume7,735,544
Avg. Volume7,675,152
Market Cap316.079B
Beta (5Y Monthly)0.42
PE Ratio (TTM)26.34
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.50 (0.58%)
Ex-Dividend DateJul 07, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BIOCON.NS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 1-Bristol Myers CEO says India to have largest R&D presence outside US by 2025

      U.S. drugmaker Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025, CEO Christopher Boerner said on Tuesday. The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference. Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International.

    • Reuters

      India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns

      Indian biopharmaceutical company Biocon Ltd swung to a third-quarter profit on Thursday, boosted by its biosimilars business and the sale of some of its non-core units, and said Chief Financial Officer Indranil Sen had resigned. Sen, who has been with the company for nearly a decade, resigned from the role to pursue career opportunities outside of Biocon, it said. For the latest quarter, the Bengaluru-based company reported a consolidated net profit of 6.6 billion rupees ($79.6 million), compared with a loss of 418 million rupees a year earlier.

    • Reuters

      Biocon may list biosimilars business by 2025 first half - CEO

      Indian biopharmaceutical company Biocon Ltd is planning to list its biosimilars business, a significant contributor to the company's total revenue, by the first half of 2025, a top executive said on Friday. "I would say it (listing of the biologics business) can happen any time after the second half of 2024 ... it is likely to happen in the first half of 2025," Biocon Ltd CEO and Managing Director Siddharth Mittal told Reuters. Last year, Biocon acquired U.S.-based Viatris Inc's biosimilar business.